(MedPage Today) — CHICAGO — Use of GLP-1 receptor agonists in patients with four solid tumor types was significantly associated with lower rates of progression to metastatic disease over a 5-year period, a propensity score-matched analysis…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
